Neringa's Licence Portfolio
A suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Four potential human monoclonal antibodies have been identified with broad neutralising activities in coronavirus (SARS and MERS).
A novel 3D culture methodology using stirred-tank bioreactors as a scalable platform for the production of hPSC-derived endothelial cells.
A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors.
New zinc finger peptides and encoding nucleic acid molecules that can be used for the modulation of gene expression; this has therapeutic applications for neuro-degenerative disorders like FXTAS where altered expression of genes is part of the disease aetiology.
New zinc finger peptides and encoding nucleic acid molecules that can be used for the modulation of gene expression in vitro and/or in vivo. This invention has therapeutic applications for neurological disorders such as ALS and FTD where altered expression of genes is part of the disease aetiology.
MicroRNA are important gene regulators and their expression profiles change with pathophysiology, allowing their use as biomarkers. Imperial researchers have identified differential markers that can distinguish pregnancy of unknown location (PUL).
A novel platform for production of Viral-like Particles (VLPs) used as a single vaccine against a range of viruses, including HIV, HPV, or Ebola. The invention combines two technical innovations; core platform to generate non-infectious VLPs based on the modification of Mumps or Parainfluenza 5 viruses, and a ‘pseudotyping’ technology to incorporate viral glycoproteins of choice on the surface of VLPs. As a proof of concept, the platform was used in development of modified VLPs against HIV. When used as a vaccine, VLPs boosted the production of anti-HIV antibodies better than the native virus.
The present invention relates to a novel DNA delivery vector for targeted gene therapy, medical imaging and vaccination with increased efficacy over existing technologies. The platform comprises a phagemid hybrid with phage and recombinant adeno-associated virus (AAV) components.
A novel viral delivery vector with scope for more cost-effective commercial production over existing technologies. The platform comprises a phagemid hybrid with recombinant adeno-associated virus (AAV) components.
Researchers at Imperial College London have developed two novel modifications of bacteriophages to significantly improve their efficacy as vectors for targeted gene therapy, and exploit their advantages over eukaryotic viral vectors.
Suite of microRNAs for predicting cervical shortening and preterm birth that can be measured from blood samples taken in early pregnancy (from gestation week 12 onwards).
Novel truncated fragments of von Willebrand factor (VWF) engineered by a team at Imperial College London.